9. Restructuring

In January 2017, we implemented organizational restructuring and cost reduction plans to align around our immuno-oncology business while allowing us to advance HEPLISAV-B through the FDA review and approval process. To achieve these cost reductions, we suspended manufacturing activities, commercial preparations and other long term investment related to HEPLISAV-B and reduced our global workforce by approximately 40 percent.

During the three months ended March 31, 2017 we recorded charges of $2.8 million related to severance, other termination benefits and outplacement services. Of that amount, we paid $1.9 million during the first quarter of 2017 and expect to pay approximately $0.8 million, in aggregate, in the second and third quarter of 2017.

The outstanding restructuring liabilities are included in accrued liabilities on the condensed consolidated balance sheets. As of March 31, 2017, the components of the liabilities were as follows (in thousands):

	Employee Severance and Other Benefits
Restructuring charges	$	2,783
Cash payments		(1,936	)
Balance at March 31, 2017	$	847